Pacific Biosciences of California (PACB) Projected to Post Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB) is projected to issue its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $40.68 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Pacific Biosciences of California Stock Up 13.9 %

Shares of NASDAQ:PACB opened at $1.64 on Thursday. The company has a quick ratio of 8.64, a current ratio of 9.74 and a debt-to-equity ratio of 1.97. Pacific Biosciences of California has a fifty-two week low of $1.16 and a fifty-two week high of $6.83. The stock has a market cap of $449.13 million, a price-to-earnings ratio of -1.12 and a beta of 1.92. The firm’s 50 day moving average price is $1.86 and its 200 day moving average price is $1.81.

Insider Transactions at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Oene Mark Van sold 34,405 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $2.03, for a total value of $69,842.15. Following the transaction, the insider now directly owns 1,597,454 shares of the company’s stock, valued at approximately $3,242,831.62. The trade was a 2.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. UBS Group lowered Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a report on Monday, November 11th. Scotiabank dropped their price objective on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a report on Monday, November 11th. Piper Sandler raised their target price on Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a research report on Monday, November 11th. The Goldman Sachs Group dropped their price target on shares of Pacific Biosciences of California from $2.25 to $1.75 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Pacific Biosciences of California to a “sell” rating in a research report on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $2.89.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.